Alnylam Pharmaceuticals (ALNY) vs Moderna (MRNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Moderna (MRNA) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 605.6% versus a loss of 50.2%. Over five years, ALNY leads with a +7.7% price change compared with -39.2% for MRNA. Moderna is the larger company by market cap ($89.83 billion vs $31.13 billion), about 2.9 times the size, while Alnylam Pharmaceuticals is growing revenue faster (+65.2% vs -39.9%).
Alnylam Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.4% versus -145.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | MRNA |
|---|---|---|
| Share price | $232.68 | $225.00 |
| Market cap | $31.13B | $89.83B |
| 1-day change | +3.63% | +14.21% |
| YTD return | -43.54% | +568.02% |
| 1-year return | -50.18% | +605.59% |
| 5-year return | +7.66% | -39.24% |
| P/E ratio (TTM) | 39.24 | — |
| Forward P/E | 18.73 | — |
| EPS (TTM) | $5.93 | $-7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | $1.94B |
| Revenue growth (YoY) | +65.19% | -39.93% |
| Net income (latest FY) | $313.75M | $-2.82B |
| Gross margin | 81.77% | 55.35% |
| Operating margin | 13.51% | -158.13% |
| Net margin | 8.45% | -145.16% |
| 52-week high | $495.55 | $225.00 |
| 52-week low | $197.81 | $22.28 |
| Distance from 52-week high | -53.05% | 0.00% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +59.50% | -46.22% |
| Average volume | 1.78M | 17.95M |
| Shares outstanding | 133.81M | 399.24M |
| Employees | 2,500 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Moderna is about 2.9 times larger than Alnylam Pharmaceuticals by market value ($89.83B vs $31.13B).
- MRNA has outperformed ALNY by 655.8 percentage points over the past year.
- Alnylam Pharmaceuticals is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -145.2 cents for Moderna.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs -39.93%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
ALNY vs MRNA FAQ
Which is bigger, Alnylam Pharmaceuticals or Moderna?
Moderna (MRNA) is larger, with a market capitalization of $89.83B compared with $31.13B for Alnylam Pharmaceuticals (ALNY).
Which stock has performed better over the past year, ALNY or MRNA?
MRNA returned +605.59% over the past 12 months, compared with -50.18% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Are Alnylam Pharmaceuticals and Moderna in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Alnylam Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Moderna.